#USA #San Diego #KTX-1001 #K36 Therapeutics #Multiple Myeloma

K36 Therapeutics Showcases KTX-1001 at ASH 2024

K36 Therapeutics, a burgeoning biotech firm, has made significant strides in combating multiple myeloma, particularly in patients exhibiting the challenging t(4;14) translocation. At the upcoming 66th American Society of Hematology (ASH) Annual Meeting, which will occur from December 6-10, 2024, in San Diego, California, the company is set to present pivotal findings related to its lead compound, KTX-1001, and the promising KTX-1029 program.

The anticipation surrounding KTX-1001 is unprecedented as it represents a first-in-class MMSET/NSD2 inhibitor aimed at managing relapsed and refractory multiple myeloma. This will mark the unveiling of clinical results from the drug’s dose escalation phase in a Phase 1 study designed to assess its safety and efficacy.

Recent Developments in KTX-1001

The presentations will reveal the initial data on dose escalation and the pharmacological characteristics of KTX-1001. Dr. Pierre Bories, a hematologist associated with K36, expressed enthusiasm about the findings, noting that the data showcases an increase in patient exposure to KTX-1001 and a significant reduction in the H3K36me2 biomarker, which indicates effective target engagement. This direct correlation between dosage and biomarker reduction suggests that KTX-1001 may offer a promising treatment avenue for those with the t(4;14) alteration inherent in their condition.

Dr. Terry Connolly, President, and CEO of K36 Therapeutics, echoed Dr. Bories' excitement, highlighting the growing momentum in patient enrollment since their previous ASH presentation. He emphasized the importance of KTX-1001 in addressing the urgent need for effective oral treatment options for high-risk myeloma patients, who often find themselves with few therapeutic alternatives.

Insights from the Poster Presentations

Among the notable presentations scheduled at ASH are:

• - Title: First Results from the Dose Escalation Part of the Phase 1 Study of KTX-1001

- Poster Number: 3370
- Session Name: Multiple Myeloma Pharmacologic Therapies
- Date & Time: December 8, 2024, 6:00 PM - 8:00 PM PST

• - Title: Characterization of the Biochemical Activity of KTX-1001

- Poster Number: 2205
- Session Name: Chemical Biology and Experimental Therapeutics
- Date & Time: December 7, 2024, 5:30 PM - 7:30 PM PST

• - Title: KTX-1029, a Potent, Selective MMSET/NSD2 Inhibitor Is Effective in t(4;14) Multiple Myeloma Preclinical Models

- Poster Number: 1878
- Session Name: Multiple Myeloma and Plasma Cell Dyscrasias
- Date & Time: December 7, 2024, 5:30 PM - 7:30 PM PST

These presentations will focus on KTX-1001's unique mechanism among targeted therapies and how it leverages the dynamics of personalized medicine to potentially revolutionize treatment protocols.

The Future of K36 Therapeutics

Advancing into 2025, K36 is poised to commence a combination study where KTX-1001 will be employed alongside standard therapeutic agents, including proteasome inhibitors. This combined therapy aims to enhance therapeutic outcomes in patients with the specific t(4;14) genetic aberration—a significant and often difficult subgroup within multiple myeloma patients.

K36 Therapeutics' innovative approach underscores a commitment to harnessing targeted therapies that could meaningfully improve patient quality of life and survival rates. By continuing to evolve clinical strategies tailored to the unique genetic profiles and disease characteristics of multiple myeloma patients, K36 remains at the forefront of oncological advancement.

For more detailed findings, information on the full study abstracts will be available on the ASH Annual Meeting website at www.Hematology.org.

K36 Therapeutics, founded in 2021 and supported by significant venture capital firms, is dedicated to transforming the landscape of cancer care through innovative epigenetic modulators tailored to individual oncogenic pathways. To learn more about their groundbreaking work, please visit K36's website and follow their updates on LinkedIn.